Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stemis in Elderly Subjects With Mild to Moderate Frailty Syndrome
NCT07462819Phase 1Not yet recruiting
- Sponsor
- Jiyan Biomedical
- Start
- Apr 2026
- Primary completion
- Sep 2028
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Stemis in frailty syndrome (2 arms), sponsored by Jiyan Biomedical. Primary endpoints: Maximum Feasible Dose at 26 weeks, Treatment-Emergent Adverse Events at 26 weeks and 4 more. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
Stemis
03
Conditions
frailty syndrome
Beyond the preview
Go deeper on NCT07462819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07462819.